Cibus Reports Third Quarter Financial Results and Provides Business Update

Cibus, Inc. (CBUS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Cibus Reports Third Quarter Financial Results and Provides Business Update Rice herbicide-tolerance traits performed well in Latin American field trials and are now being tested by customer Interoc in its own varieties Initiated the manufacturing process for initial two biofragra

Event · Earnings
Original reporting
Published Nov 12, 2026, 9:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 9:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$CBUS
Neutral
medium confidence
Mentioned
$CBUS
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CBUSNeutralMed
01

Why it matters

The Q3 filing adds fresh financial data and operational updates, but lacks a major catalyst such as a new partnership or regulatory approval.

02

Market read

The filing is a primary source of new financial information for Cibus, offering modest trading relevance for short‑term investors.

03

What to watch

Upcoming royalty revenue from Latin American rice traits could materialize later, offering upside not captured in the short‑term reaction.

Relevance 7/10Novelty 7/10Timing: today
AlphAI · Earnings readCBUS · Q3 2026 · ended 2026-09-30

Cibus reports Q3 2026 revenue of $800 thousand and net loss of $21.9 million, with narrower losses, a cash position of $10.7 million and runway stated only into early Q1 2027

→Mixed quarter

Operating costs and the net loss fell year over year and operating cash use improved, but revenue is small, the royalty liability and its non-cash interest keep growing, stockholders' equity is negative, and the company says its cash lasts only into early Q1 2027. The main commercial catalysts (Interoc definitive agreement, Interoc trial results, biofragrance scale-up orders) are not yet reported.

Revenue
$800K
EPS · GAAP
$(0.29)
$0.15 decrease in net loss per share y/y

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenue, Q3 2026GAAP$800K––
Total revenue, nine months 2026GAAP$3.48M––
Research and development expense, Q3 2026GAAP$7.91M–$2.9 million decrease
Research and development expense, nine months 2026GAAP$25.14M––
Selling, general and administrative expense, Q3 2026GAAP$5.39M–$0.1 million increase
Selling, general and administrative expense, nine months 2026GAAP$15.89M––
Goodwill impairment, nine months 2026GAAPnot reported (dash in table)––
Total operating expenses, Q3 2026GAAP$13.31M––
Total operating expenses, nine months 2026GAAP$41.03M––
Loss from operations, Q3 2026GAAP−$12.51M––
Loss from operations, nine months 2026GAAP−$37.55M––
Royalty liability interest expense, related parties (non-cash), Q3 2026GAAP−$9.84M–$0.8 million increase
Royalty liability interest expense, related parties (non-cash), nine months 2026GAAP−$28.44M––
Other interest income, net, Q3 2026GAAP$44K––
Non-operating income, net, Q3 2026GAAP$368K–$0.4 million increase
Non-operating income, net, nine months 2026GAAP$516K––
Loss before income taxes, Q3 2026GAAP−$21.94M––
Loss before income taxes, nine months 2026GAAP−$65.29M––
Net loss, Q3 2026GAAP−$21.94M––
Net loss, nine months 2026GAAP−$65.31M––
Net loss attributable to Cibus, Inc. stockholders, Q3 2026GAAP−$21.94M––
Net loss attributable to Cibus, Inc. stockholders, nine months 2026GAAP−$65.31M––
Basic and diluted net loss per share of Class A common stock, Q3 2026GAAP$(0.29)–$0.15 decrease in net loss per share
Basic and diluted net loss per share of Class A common stock, nine months 2026GAAP$(0.89)––
Net cash used in operating activities, nine months 2026GAAP−$30.20M–approximately 19% improvement
Cash used in operating activities, Q3 2026GAAP$9.3M––
Cash and cash equivalents, September 30, 2026GAAP$10.71M––
Proceeds from issuances of securities, nine months 2026GAAP$37.41M––
Total assets, September 30, 2026GAAP$301.5M––
Total stockholders' equity (deficit), September 30, 2026GAAP−$5.67M––

Exit of 2026 and first quarter 2027 (qualitative, as stated) outlook

  • NoteExpects to exit 2026 at an annual net cash usage run-rate of approximately $35 million
  • NoteExisting cash and cash equivalents expected sufficient to fund planned operating expenses and capital expenditure into early in the first quarter of 2027, without giving effect to potential financing transactions
  • NoteInteroc trial results in Rice expected in the first quarter of 2027
  • NoteCompletion of 2026 U.S. demonstration trials expected in the fourth quarter of 2026
  • NoteTransfer of John Innes Centre Canola material now expected in the fourth quarter of 2026 (previously third quarter of 2026)
  • NoteBiofragrance scale-up orders expected in the second half of 2026: not yet received

Capital returns

  • No share repurchases or dividends are reported in the filing.
  • Proceeds from issuances of securities were $37,409 thousand in the nine months ended September 30, 2026, against $50,100 thousand in the year-ago period, and costs paid related to issuances of securities were $5,562 thousand against $2,202 thousand.
  • Payment of taxes related to restricted stock units withheld from employees was $(187) thousand for the nine months 2026.

What drove it

  • R&D expense fell by $2.9 million. The company attributes this primarily to a $1.5 million decrease in personnel-related expenses from lower headcount, a $0.9 million decrease in facilities-related expenses from cost reduction initiatives including the closure of the Oberlin facility and wind-down of operations at the Roseville, Minnesota facility, and a $0.4 million decrease in product development and lab supply costs from a streamlined focus and prioritization of development programs.
  • SG&A expense rose by $0.1 million. The company attributes this to a $0.1 million increase in facilities-related expenses from relocating equipment from the Roseville, Minnesota facility and a $0.1 million increase in professional fees, which it says reflects a $0.4 million increase from a litigation liability reduction in the prior-year period, partially offset by a $0.3 million decrease from cost reduction initiatives. A $0.2 million decrease in personnel-related expenses from lower headcount is also cited.
  • Royalty liability interest expense (non-cash) rose by $0.8 million, which the company attributes to the recognition of interest expense on the accumulating Royalty Liability balance.
  • Non-operating income, net rose by $0.4 million, which the company says is primarily driven by grant income recognized for research work performed by Cibus.
  • The company states that the net loss per share improvement of $0.15 is primarily driven by the $2.4 million decrease in net loss drivers described above and a year-over-year increase in weighted average shares outstanding.
  • Revenue of $800 thousand includes billing under a new partner-funded research program for Indian Mustard, which began in Q3 2026 and is recognized in revenue.
  • The company states that its cost reduction actions during 2026 included workforce reductions, consolidating laboratory activities at its Nancy Ridge facility in San Diego, and a review of corporate and back-office functions.

Concerns

  • Cash and cash equivalents of $10,710 thousand are stated to fund planned operations only into early in the first quarter of 2027, excluding potential financing transactions. The company also says it could use its capital resources sooner than expected.
  • Total stockholders' deficit of $(5,670) thousand at September 30, 2026, against equity of $21,829 thousand at December 31, 2025.
  • The royalty liability, related parties, rose to $263,362 thousand from $234,923 thousand at December 31, 2025, and the related interest expense ($9,843 thousand in Q3 2026) is non-cash and accumulates on the balance.
  • Quarterly revenue is $800 thousand, against a net loss of $21,941 thousand.
  • The Interoc commercialization agreement is still in negotiation and has not been signed. The company says it continues to advance toward a definitive agreement.
  • Biofragrance scale-up orders expected in the second half of 2026 have not been received. The company says it has received requests for larger quantities of two biofragrance products, which it describes as requests to advance product development.
  • The transfer of edited Canola material to the John Innes Centre slipped from Q3 2026 to Q4 2026.
  • The biofragrance peak revenue opportunity of up to approximately $100 million reflects a direct-sales model, which the company says replaces the previously assumed royalty model.

What to watch

  • Whether the Interoc definitive commercialization agreement is signed, and the timing and terms of any royalty on Rice acres.
  • Interoc's trial results in its own Rice varieties, expected in Q1 2027.
  • Whether scale-up orders for the initial biofragrances arrive in the second half of 2026, and partner review of the next ingredients in Q4 2026.
  • Whether the company reaches an annual net cash usage run-rate of approximately $35 million by the exit of 2026, as stated.
  • Any financing transactions, given that the stated cash runway runs only into early Q1 2027 without them.
  • Growth in the royalty liability balance and related non-cash interest expense.
  • Completion of the 2026 U.S. demonstration trials in Q4 2026, and the Brazil regulatory dossier for Rice trait material.
  • Material transfer agreements with the John Innes Centre, expected in Q4 2026.

Balance sheet and cash flow

  • Cash and cash equivalents were $10,710 thousand at September 30, 2026, up from $9,923 thousand at December 31, 2025.
  • Royalty liability, related parties, was $263,362 thousand at September 30, 2026, up from $234,923 thousand at December 31, 2025.
  • Total liabilities were $307,153 thousand, against total assets of $301,483 thousand, giving a stockholders' deficit of $(5,670) thousand at September 30, 2026, compared with stockholders' equity of $21,829 thousand at December 31, 2025.
  • Goodwill was $232,516 thousand at both September 30, 2026 and December 31, 2025.
  • Net cash used in operating activities was $(30,199) thousand for the nine months 2026, against $(37,171) thousand a year earlier, and net cash provided by financing activities was $31,023 thousand, against $47,106 thousand.
  • Net increase in cash and cash equivalents was $787 thousand for the nine months 2026, against $9,453 thousand a year earlier.
  • Purchases of property, plant and equipment were $(73) thousand for the nine months 2026, against $(492) thousand a year earlier.
  • Accounts payable fell to $5,423 thousand from $8,070 thousand at December 31, 2025, and deferred revenue to $7 thousand from $536 thousand.

Analysis

Cibus reported Q3 2026 revenue of $800 thousand, against $615 thousand a year earlier, and a net loss of $21,941 thousand, against $24,303 thousand. Nine-month revenue was $3,475 thousand against $2,582 thousand, and the nine-month net loss was $65,308 thousand against $100,253 thousand. The prior-year nine-month figure included a goodwill impairment of $20,950 thousand, which is not repeated in 2026, so the nine-month comparison is distorted by that charge. Loss per share was $(0.29) for the quarter against $(0.44) a year earlier. The filing reports revenue as a single line with no segment split. The company describes the quarter's revenue as including billing under a new partner-funded Indian Mustard program, and grant income of $368 thousand within non-operating income, net.

Cost reduction is the clearest change in the quarter. R&D fell to $7,913 thousand from $10,784 thousand, and the company attributes the decrease mainly to lower headcount, facility closures and a narrower program focus. SG&A was roughly flat at $5,393 thousand against $5,269 thousand. Total operating expenses fell to $13,306 thousand from $16,053 thousand, and the loss from operations narrowed to $(12,506) thousand from $(15,438) thousand. The royalty liability interest expense, which is non-cash, rose to $(9,843) thousand from $(9,030) thousand as the royalty liability balance accumulated to $263,362 thousand at September 30, 2026. Because this charge sits below operating loss, the operating improvement does not carry through to net loss at the same rate.

On cash, net cash used in operating activities for the nine months was $(30,199) thousand against $(37,171) thousand, which the filing describes as an improvement of approximately 19%. Quarterly operating cash use was $9.3 million. Cash was $10,710 thousand at September 30, 2026, and the company says existing cash covers planned operating and capital expenditures only into early in the first quarter of 2027, excluding potential financing. Financing has been the main source of funds, with $37,409 thousand of securities proceeds in the nine months against $5,562 thousand of issuance costs. Total stockholders' equity moved to a deficit of $(5,670) thousand from $21,829 thousand at December 31, 2025.

The guidance is qualitative. The company expects to exit 2026 at an annual net cash usage run-rate of approximately $35 million. It gives no revenue, margin or expense guidance and no prior outlook was provided for comparison. Commercial progress is mainly in announcements and timelines. The Interoc trait test results are expected in Q1 2027, the definitive Interoc agreement is still being negotiated, the biofragrance scale-up orders have not yet been received, and the John Innes material transfer slipped into Q4 2026. The company also says its biofragrance peak revenue opportunity of up to approximately $100 million now reflects a direct-sales model rather than the previously assumed royalty model, which the filing presents as a change in commercial structure.

Management, verbatim

Three months ago I described three ways our platform creates value: platform programs that generate revenue today, royalties as our traits reach acres, and partnerships that deepen over time. Each of these moved closer this quarter.

Craig Wichner, Chief Executive Officer

Not in the filing

stated, not guessed
  • Prior-quarter (June 30, 2026) figures for all income statement lines, since the filing presents only the three- and nine-month periods
  • Year-over-year percentage changes for revenue, operating expenses and net loss; the filing gives dollar changes only for some lines
  • Year-ago Q3 2025 net cash used in operating activities (the filing gives only the nine-month comparison in the statement and the quarterly figure of $9.3 million without a prior-year counterpart)
  • Year-ago September 30, 2025 cash and cash equivalents on the balance sheet (the filing gives December 31, 2025 only)
  • Revenue breakdown by product, program or partner, since revenue is reported as a single line
  • Segment information, since the filing reports no operating segments
  • Quantitative guidance for revenue, gross margin, operating expenses or tax rate
  • Gross margin, since the filing presents no cost of sales line
  • Consensus estimates, analyst expectations and any share price reaction, none of which appear in the filing
  • Non-GAAP measures, since none are presented in the filing
  • Amount of any financing transactions the company may pursue, and the terms of the stated cash runway
  • Quantity and timing of Interoc royalty payments and biofragrance revenue, beyond the peak estimates stated in the filing

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

Cibus is a Nasdaq‑listed company developing gene‑edited crop traits and sustainable bio‑fragrance ingredients.

Company-level read

Ticker impact

$CBUSNeutralMedium confidence
Context

Cibus filed its Form 8‑K reporting Q3 results, including a 19% YoY drop in cash used and guidance to exit 2026 with ~$35 M annual net cash usage run‑rate.

Expected impact

likely modest pressure as investors digest lower cash usage and upcoming royalty outlook, with no clear directional catalyst.

Evidence & confidence

First‑time disclosure of Q3 numbers gives new data, but the scale is limited and no major contract or guidance shift is announced.

Market effects

Provides an update on gene‑edited crop traits, modestly informing the ag‑biotech sector.

Limited to investors focused on US‑listed biotech micro‑caps.

Low; the filing does not affect broader market indices.

Counterpoint

The cash‑usage decline may signal tighter cost discipline, potentially supporting the stock despite modest scale.

Key entities

  • Cibus, Inc.

    Biotech firm focused on gene‑edited crops and bio‑fragrances.

  • Interoc

    Customer testing Cibus rice traits in Latin America.

Every CBUS earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$CBUSMed

Cibus Q2 Earnings Call Highlights

Cibus (NASDAQ:CBUS) reported cash and cash equivalents of $20.4 million as of June 30. Management said cash burn declined 19% sequentially and 31% year over year, with existing cash expected to fund operations and capex into early Q1 2027. Guidance updates include shifting an initial Latin America rice launch to 2028 and targeting biofragrance revenue of $20 million to $40 million when commercialized.

$CBUSMedAI 8/10

Europe Recognizes Nature-Based Plant Improvement, Opening a New Pathway for Cibus

Cibus, Inc. (Nasdaq: CBUS) said the EU has adopted rules treating crops improved without adding foreign DNA as conventionally bred, not as transgenic GMOs. The company said this validates its gene-editing approach developed over nearly 25 years and could help European farmers adopt traits such as disease resistance and reduced chemical use. Cibus expects some traits to qualify under the EU “Category 1” fast lane.

$XPMedAI 8/10

XP Q3 2026 slides: asset growth strong, but margin pressure evident

XP Inc. reported Q3 2026 earnings with total client assets up 15% YoY to R$2.2T, but net margins contracted to 26.9%. Revenue grew 8% YoY to R$5.3B, while SG&A expenses rose 12% YoY. Shares fell 4.26% post-earnings. The company is diversifying revenue, with non-investment revenues now 20% of retail revenue. Management expects 10% annual top-line growth in 2027.